Supplemental Figures from the <i>rars–mad1l1</i> Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma

Qian Zhong,Zhi-Hua Liu,Zhi-Rui Lin,Ze-Dong Hu,Li Yuan,Yan-min Liu,Ai-Jun Zhou,Li-Hua Xu,Li-Juan Hu,Zi-Feng Wang,Xin-Yuan Guan,Jia-Jie Hao,Vivian W.Y. Lui,Ling Guo,Hai-Qiang Mai,Ming-Yuan Chen,Fei Han,Yun-Fei Xia,Jennifer R. Grandis,Xing Zhang,Mu-Sheng Zeng
DOI: https://doi.org/10.1158/1078-0432.22465245
2023-01-01
Abstract:S1. Identification of RARS-MAD1L1 by RNA-Seq. S2. RARS-MAD1L1 promotes the proliferation and colony-formation ability of p53-/- MEFs and S26 cells. S3. RARS-MAD1L1 enhances CSC properties in NPC cells. S4. Knockdown of endogenous RARS-MAD1L1 reduces the CSC characteristics of C666-1 cells. S5. Knockdown of RARS-MAD1L1 reduces the oncogenic function of S26 cells induced by RARS-MAD1L1. S6. RARS-MAD1L1 overexpression presents a stronger oncogenic function than wild-type RARS in NPC cells. S7. Knockdown of c-Myc reduces the expression of ABCG2 S8. Schematic illustration of the mechanism through which RARS-MAD1L1 induces cancer stem cell properties and therapeutic resistance through the FBP1/c-Myc axis.
What problem does this paper attempt to address?